Abstract

A computer-implemented Alamouti shared secret key physical layer security method enables secure communication between first and second network nodes in a communications network. Each node, equipped with M antenna elements, exchanges pilot signals to reconstruct channels via singular value decomposition. The first node transmits reference signals, rotated by a random unitary matrix, and their complex conjugates across time slots or frequency sub-channels. Both nodes generate secret keys, divide them into sequences, and encode them using a precoding matrix and universal codebook indices. Encoded sequences are transmitted, received, and decoded through singular value decomposition or machine learning to estimate the counterpart's secret key. Concatenating estimated and local secret keys forms a whole secret key, used for ongoing secure communication. The method operates over Open Radio Access Network (O-RAN) E2 interfaces, supporting centralized or distributed units, ensuring robust physical layer security.

IPC Classes  ?

• H04W 12/037 - Protecting confidentiality, e.g. by encryption of the control plane, e.g. signalling traffic
• H04B 7/0456 - Selection of precoding matrices or codebooks, e.g. using matrices for antenna weighting
• H04L 5/00 - Arrangements affording multiple use of the transmission path

Abstract

Embodiments are directed to an automated system that provides statistical confirmation of the non-infiltrated state of a functioning PIV and a clear signal associated with an infiltrated PIV identifying conditions associated with infiltration/extravasation before rather than after the onset of a noxious event such as tissue edema or damage.

IPC Classes  ?

• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters

Abstract

Aspects herein relate to methods, compositions, and systems directed to the discovery that TSG-6 secretion by cancer-associated fibroblasts (CAFs) in a tumor, in some instances, leads to a poor response to immune checkpoint therapies in the tumor. Inhibition of TSG-6 in certain cancers, in combination with immune checkpoint therapies, led to an improved therapeutic response to the immune checkpoint therapies. Such findings provide methods and compositions for diagnosing, prognosing, and treating certain cancers.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present disclosure is concerned with substituted quinazoline-2,4-diamines and compositions for the treatment of disorders associated with altered expression of SMARCA2 and/or SMARCA4 such as, for example, cancer (e.g., sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents
• C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Abstract

One embodiment of a portable suction device as described herein is called a suction combat ready advanced multifunctional machine (SCRAMM). A SCRAMM is a portable suction device designed and developed to be used as both in-field hospital suction device and combat ready suction device. The device can be used in a horizontal or vertical position, i.e., the device is position independent.

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61M 27/00 - Drainage appliances for wounds, or the like
• A61M 16/04 - Tracheal tubes
• A61M 16/08 - BellowsConnecting tubes

Abstract

e.g.,e.g., two or more, or three or more genotypes selected from norovirus GII genotypes GII.2, GII.3, GII.4, GII.6, GII.12, GII.17 and GII.14; methods of producing the antibodies; and methods of treating a patient exposed to norovirus or infected with norovirus using such antibodies.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral

Abstract

The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO decreases or increases exclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Embodiments described herein relate to methods and compositions for diagnosis, monitoring, classifying, staging and determination of treatment regimens in subjects with or at risk of kidney disease and/or all-cause mortality by determining the level of an amino acid or nucleic acid in a biological fluid, such as urine. In certain aspects the subjects are diagnosed with diabetes (or other underlying risk factor for kidney disease such as hypertension) and have normal levels of urine albumin. Additionally, disclosed herein are methods of treating a condition of fibrosis by inhibiting production or function of adenine.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a polysaccharide comprising pendant amides, methods of making thereof, and copolymers, nanoparticles, compositions, thermoplastics, and membranes comprising the polysaccharide.

IPC Classes  ?

• C07H 1/00 - Processes for the preparation of sugar derivatives
• A21D 2/18 - Carbohydrates

Abstract

Sulfonyl-azole compounds (e.g., sulfonyl-imidazole compounds) and their use as covalent ligands for reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, e.g., to selectively form modified proteins and/or to alter the biological activity of the proteins are described. Sulfonyl-imidazole compounds for inhibiting particular proteins, such as prostaglandin reductase 2 (PTGR2) and glutathione S-transferase (GST) enzymes, are also described.

IPC Classes  ?

• C07D 233/84 - Sulfur atoms
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A thermal switch includes a cooling liquid reservoir, an acoustic droplet generator, and an array of micro-nozzles. A control signal can indicate to the acoustic droplet generator to generate an acoustic wave which pushed cooling liquid from the cooling liquid reservoir through the array of micro-nozzles. The micro-nozzles utilize an inverted geometry where the entrance is larger than the exit to cause an increase in pressure to allow a specific amount of cooling liquid to be released as a droplet. The droplets from the array of micro-nozzles form a droplet array on a heat component thereby allowing a thermal energy transfer to take place, where the thin liquid film absorbs the thermal energy and changes state to a vapor. The heat component can be a heat sink, a chip, an integrated circuit, or other type of component.

IPC Classes  ?

• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

Embodiments are directed to a toxic tau conformation-specific monoclonal antibodies as well as an α-Syn monoclonal antibodies. Certain compositions are include antibodies loaded into or conjugated to micelles as a carrier for improved intracellular delivery in the brain. In certain aspects the intranasal route for delivery was used, leveraging the direct nose- to-brain anatomic pathway, recognized as a viable, non-invasive, safe approach for effective drug-delivery in the brain. In certain other aspects the monoclonal antibodies are used as combination therapies.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Engineered bacterial spores have been engineered to express a lanthanide binding protein. This binding protein is capable of capturing rare earth elements (REEs). There are various methods which can be used to capture REEs by using these spores.

IPC Classes  ?

• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae
• C22B 59/00 - Obtaining rare earth metals
• C01F 17/20 - Compounds containing only rare earth metals as the metal element

Abstract

The present disclosure relates to engineered selenocysteine-specific elongation factor (SelB) variant and methods of generating and using the variants thereof.

IPC Classes  ?

• C07K 14/245 - Escherichia (G)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 9/10 - Transferases (2.)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12P 21/00 - Preparation of peptides or proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/16 - YeastsCulture media therefor
• C12N 1/20 - BacteriaCulture media therefor

Abstract

An aptamer which selectively produces a detectable signal in the presence of CoA and methods of using the same.

IPC Classes  ?

• C12Q 1/6825 - Nucleic acid detection involving sensors
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

The present disclosure provides a new approach to cancer immunotherapy, focusing on restoring p53 function in immune cells with TP53 mutations. This strategy seeks to counteract exhaustion and bolster the anti-tumor activity of immune cells, thereby enhancing the efficacy of current immune cell therapies for cancer. The present disclosure provides methods for restoring anti-tumor activity of an immune cell, including contacting the immune cell with a p53 reactivator, wherein the immune cell includes a TP53 gene mutation.

IPC Classes  ?

• C07K 14/475 - Growth factorsGrowth regulators
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Described herein are methods and systems for capturing carbon dioxide gas from a gas stream.

IPC Classes  ?

• B01D 53/46 - Removing components of defined structure
• B01D 53/62 - Carbon oxides
• B01D 53/74 - General processes for purification of waste gasesApparatus or devices specially adapted therefor
• B01D 53/34 - Chemical or biological purification of waste gases

Abstract

Embodiments are directed to an automated system that provides statistical confirmation of the non-infiltrated state of a functioning PIV and a clear signal associated with an infiltrated PIV identifying conditions associated with infiltration/extravasation before rather than after the onset of a noxious event such as tissue edema or damage.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61M 1/38 - Removing constituents from donor blood and returning remainder to body
• G01L 27/00 - Testing or calibrating of apparatus for measuring fluid pressure
• G01M 3/28 - Investigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for pipes, cables, or tubesInvestigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for pipe joints or sealsInvestigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for valves
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G16Z 99/00 - Subject matter not provided for in other main groups of this subclass

Abstract

Classical computer systems can generate certified random bit strings using an untrusted quantum computer. The classical computer system can issue a sequence of challenges to the quantum computer, with each challenge involving execution of an apparently-random quantum circuit generated by the classical client. By executing the quantum circuits, the quantum computer can generate a high-entropy bit sequence, and the classical client can use the high-entropy bit sequence to generate sequences of random bits. The classical client can use models of quantum probability distributions for at least some of the challenges to verify that the bit sequence was generated by a quantum computer executing the quantum circuit generated by the classical client, thereby supporting certification of the randomness of the sequence of bits.

IPC Classes  ?

• G06F 7/58 - Random or pseudo-random number generators
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computersPlatforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing

Abstract

The present invention is concerned with novel CRISPR-Cas systems which are configured to detect the presence of a target nucleic acid in a sample through activation of secondary nucleases which bind and cleave a nucleic acid probe modified with a (e.g.) fluorophore/quencher moieties, where a change in the property of the probe (e.g. modified fluorescence) reflects the presence of the target nucleic acid in a sample to be tested.

IPC Classes  ?

• C12Q 1/6813 - Hybridisation assays
• C12N 9/22 - Ribonucleases

Abstract

Methods, systems, and apparatuses are described for estimating the force acting on at least one joint of a user while the user engages at least one virtual object within a virtual environment. Motion data associated with joint data of at least one joint of a user may be received from a sensor. The joint data may be used to determine force information. The force information may be used to determine user strength associated with the at least one joint.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A63F 13/56 - Computing the motion of game characters with respect to other game characters, game objects or elements of the game scene, e.g. for simulating the behaviour of a group of virtual soldiers or for path finding
• G02B 27/01 - Head-up displays
• G06V 40/20 - Movements or behaviour, e.g. gesture recognition

Abstract

A molten salt reactor system includes a fuel salt system and a coolant salt system. The fuel salt system is configured to circulate a molten fuel salt through a molten salt loop. The coolant salt system is configured to circulate a coolant salt through a coolant loop. The molten salt reactor system further includes a heat exchanger arranged along the molten salt loop and the coolant loop. The heat exchanger is configured to transfer heat from the molten fuel salt of the molten salt loop to the coolant salt of the coolant loop. The heat exchanger is configured to permit gravitational draining of at least one of the molten fuel salt or the coolant salt upon a shutdown event.

Abstract

A method of decision tree split selection is provided. The method comprises scanning, in a data source, all values of a feature and example labels. Intermediate statistics information of size O(N×C) are prepared, wherein N is the number of unique values of the feature and C is the number of label classes. A set of the N unique values of the feature are prepared with time cost O(N×C). The process then loops N times to compute heuristic scores for all splits of each unique value. Each loop has a time cost O(C). The time complexity of decision tree split selection for a single feature is O(M+N×C), wherein M is the number of examples of the feature. A model is trained in real-time with decision tree splits selected according to the heuristic scores.

IPC Classes  ?

• G06N 20/00 - Machine learning

Abstract

The present disclosure relates to a barcoded RNA comprising a first shield sequence at the 5′ end of the barcoded RNA, a barcode sequence, a scaffold sequence, a capture sequence, and a second shield sequence at 3′ end of the barcoded RNA. The present disclosure also provides for methods of performing single-cell RNA sequencing using the barcoded RNA. The present disclosure also provides for libraries including the barcoded RNA.

IPC Classes  ?

• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/09 - Tumour cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms

Abstract

RNA-targeting Cas12a2 complex allows for rationale design of Cas12a2 into a versatile enzyme capable of non-specifically degrading distinct types of nucleic acid targets depending on mutations of the active site residues and residues that stabilize bound targets. These mutations allow for tuning of output signal associated with RNA detection. By mutating specific residues, indiscriminate single-stranded RNase and DNase and double-stranded DNase activity can be modified to only cleave single-stranded DNA and single-stranded RNA, or only single-stranded DNA. This allows for diagnostic tools which can provide a detection. Residues involved in binding the non-self vs. self-recognition signal (PFS) can also be modified so larger subsets of nucleic acid targets can be recognized.

IPC Classes  ?

• C12N 9/22 - Ribonucleases

Abstract

The present invention provides optimized fluorogenic aptamers (FAPs), as well as methods of generating and identifying the optimized FAPs. Further provided are split FAPs (sFAPs) that bind target nucleic acid molecules and multiplexed methods of detecting nucleic acids, such as viral RNA, using the FAPS and sFAPs.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Compounds comprising sulfonyl-purine or sulfonyl-purine analog bonds are described for use as electrophiles in sulfonyl-purine (SuPUR) chemistry. Also described is the use of SuPUR and/or SuPUR chemistry for proteome labeling of reactive amino acid residues and for developing new covalent therapeutic agents that selectively modify select amino acid residues (e.g., tyrosine or lysine residues) in biologically active proteins and peptides, such as amyloid-beta (Aβ)-binding alcohol dehydrogenase (ABAD), guanine nucleotide binding protein alpha stimulating activity polypeptide (GNAS), alpha/beta-hydrolase domain 10 (ABHD10), glutathione S-transferase pi 1 (GSTP1), glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1), poly(ADP-ribose) polymerase 2 (PARP2), and acetyl-CoA acetyltransferase 2 (ACAT2) proteins.

IPC Classes  ?

• C07D 473/00 - Heterocyclic compounds containing purine ring systems
• C07D 487/04 - Ortho-condensed systems
• C07D 235/22 - BenzimidazolesHydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention contemplates a method of treating a mammalian skin wound that extends at least into the epidermal layer of the skin of a subject mammal that comprises treating the wound in the substantial absence of actinic light by topical application of an aqueous pharmaceutical composition containing a wound closure-assisting amount of rose bengal, a lactone, salt, ester or amide hereof dissolved or dispersed therein as well as gel-inducing amount of a thickening agent (gellant) that causes the aqueous pharmaceutical composition to gel at a temperature of about 33° to about 40° C. The treated wound is thereafter covered with a dressing that is opaque to actinic light at least in the area over the wound. This treatment method is repeated a plurality of times over the following up to about fifteen days or until the wound is closed, whichever time of time is shorter.

IPC Classes  ?

• A61K 9/10 - DispersionsEmulsions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

An exemplary system and method are disclosed for power control of a set of power sources or loads employing a differential power processing (DPP) assembly having a set of DPP units coupled to an energy storage module in abus, in which the energy storage module is extensively sized to mitigate transient conditions propagated by the set of power sources or loads to provide an extended controllable time window for the individual DPP unit to reduce control requirements for the DPP units. The individual DPP unit in the assembly would push or pull, differentially, only power to the power source or load to minimize its respective operation while maximizing the utilization of the respective power source or maintaining stability of the bus for the loads.

IPC Classes  ?

• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers
• B60L 53/51 - Photovoltaic means
• B60R 16/033 - Electric or fluid circuits specially adapted for vehicles and not otherwise provided forArrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for electric for supply of electrical power to vehicle subsystems characterised by the use of electrical cells or batteries
• H02J 3/32 - Arrangements for balancing the load in a network by storage of energy using batteries with converting means
• H02J 9/06 - Circuit arrangements for emergency or stand-by power supply, e.g. for emergency lighting in which the distribution system is disconnected from the normal source and connected to a standby source with automatic change-over
• H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only

Abstract

An embodiment includes an apparatus for coupling a user to a robot to provide robot-assisted physical therapy to the user. Other embodiments are described herein.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising
• A61F 2/54 - Artificial arms or hands or parts thereof
• A61F 2/58 - ElbowsWrists
• A61F 2/78 - Means for protecting prostheses or for attaching them to the body, e.g. bandages, harnesses, straps, or stockings for the limb stump
• B25J 9/00 - Programme-controlled manipulators

Abstract

Provided herein is a method for treating a human subject with Alzheimer's Disease (AD) having an AD metabolomic phenotype, the method comprising: obtaining or having obtained a blood sample from the human subject with Alzheimer's disease; measuring the levels of metabolites in the blood sample; applying an algorithm to the measured metabolite levels, the algorithm generating a metabolomic score based on a comparison of the measured metabolites levels to reference metabolites levels; identifying the human subject with Alzheimer's Disease as having an AD metabolomic phenotype based on the metabolomic score; wherein the algorithm is selected from a machine learning algorithm, a clustering algorithm, a random forest algorithm, a support vector machines algorithm, a radial basis function algorithm and a combination thereof.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention discloses an integrated non-intrusive, safe and user-friendly electroencephalography (EEG) system capable of classifying signals generated from both Event Related Potential (ERP) based steady-state visually evoked potential (SSVEP) and pure cognition, leveraging Riemannian Geometry-based signal classification algorithms for precise command generation. The system seamlessly combines SSVEP-based visual stimuli with cognition-based EEG signals to provide a comprehensive interface for brain-computer interaction (BCI) applications. Riemannian Geometry techniques are employed for robust signal classification and efficient command generation, enhancing the system's accuracy and reliability.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• A61G 5/00 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs

Abstract

The present invention contemplates a method of treating a mammalian skin wound that extends at least into the epidermal layer of the skin of a subj ect mammal that comprises treating the wound in the substantial absence of actinic light by topical application of an aqueous pharmaceutical composition containing a wound closure-assisting amount of rose bengal, a lactone, salt, ester or amide hereof dissolved or dispersed therein as well as gel-inducing amount of a thickening agent (gellant ) that causes the aqueous pharmaceutical composition to gel at a temperature of about 33° to about 40° C. The treated wound is thereafter covered with a dressing that is opaque to actinic light at least in the area over the wound. This treatment method is repeated a plurality of times over the following up to about fifteen days or until the wound is closed, whichever time of time is shorter.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

e.g.e.g.e.g., to image metal ions spatially.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

ηjj) of up to 10 A cm-2 for 1,000 hours with negligible degradation, and outperforms the state-of-the-art transition metal- and even noble metal-based catalysts.

IPC Classes  ?

• C01G 39/02 - OxidesHydroxides
• B01J 23/28 - Molybdenum
• B01J 27/22 - Carbides
• C01B 32/907 - OxycarbidesSulfocarbidesMixture of carbides

Abstract

Compounds comprising phosphorous-azole electrophiles are described. Also described is the use of these compounds in phosphorous-azole exchange (PhAzE) chemistry for labeling the proteome and in developing new covalent therapeutic agents that selectively modify select amino acid residues in biologically active proteins and peptides. The PhAzE compounds can target amino acid residues other than cysteine, such as, for example serine, threonine, tyrosine, and lysine. Covalent modification of serine hydrolases is also described.

IPC Classes  ?

• C07F 9/6584 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Goods & Services

Pharmaceuticals, namely, for chronic diseases, such as cardiovascular disease; pharmaceuticals, namely, for chronic diseases, such as diabetes Automated label printing machine for labeling pharmaceuticals; Automated packing machine for packing pharmaceuticals; Automated storage, retrieval, and tracking machines for handling and distributing pharmaceutical products Downloadable computer software for use with pharmaceutical automation system; Downloadable computer application software for mobile phones, namely, software for pharmaceutical automation system Automated medical device for dispensing pharmaceutic Software as a service (SAAS) services featuring software for use with pharmaceutical automation system

Goods & Services

Pharmaceuticals, namely, for chronic diseases, such as cardiovascular disease; pharmaceuticals, namely, for chronic diseases, such as diabetes Automated label printing machine for labeling pharmaceuticals; Automated packing machine for packing pharmaceuticals; Automated storage, retrieval, and tracking machines for handling and distributing pharmaceutical products Downloadable computer software for use with pharmaceutical automation system; Downloadable computer application software for mobile phones, namely, software for pharmaceutical automation system Automated medical device for dispensing pharmaceutic Software as a service (SAAS) services featuring software for use with pharmaceutical automation system

Abstract

The present technology relates to a process for producing a coated solid-state electrolyte comprising a metal-based coating layer deposited on at least a portion of a surface of a solid-state electrolyte, the process comprising the steps of: (i) depositing a precursor powder of a metal-based coating material on at least a portion of a surface of a solid-state electrolyte; (ii) subjecting the precursor powder of the metal-based coating material to a rapid heating method to produce a melted metal-based coating material; and (iii) solidifying the melted metal-based coating material to produce the coated solid-state electrolyte. Also described are coated solid-state electrolytes obtained by said process as well as electrochemical cells and batteries comprising said coated solid-state electrolytes. For instance, the battery can be a lithium battery or a lithium-ion battery.

IPC Classes  ?

• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0562 - Solid materials
• H01M 10/058 - Construction or manufacture

Abstract

Various implementations include a fluoroscopic mobile device for use with a patient disposed on a support apparatus. The device includes a base, a support arm, an x-ray tube, and an image intensifier. The support arm extends from the base, the support arm comprising a first arm portion and a second arm portion. Each of the first arm portion and the second arm portion has a proximal end proximal to the base and a distal end opposite the proximal end. The x-ray tube is coupled to the distal end of the first arm portion. The image intensifier is coupled to the distal end of the second arm portion. The x-ray tube is configured to be disposed above the patient relative to a gravitational direction when the system is in use. The image intensifier is configured to be disposed between the patient and the support apparatus when the system is in use.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

Provided are methods of treating a cancer that co-expresses one or more placental alkaline phosphatase (ALPP) proteins and a cancer target antigen in a patient in need thereof, comprising administering to the patient a treatment regimen wherein the treatment regimen comprises administration of one or more standard-of-care inhibitor or anti-proliferative agents that increase cell surface expression of the one or more ALPP proteins and one or more ALPP protein-targeting agents. Also provided are methods of selecting a patient having a cancer that co-expresses one or more placental alkaline phosphatase (ALPP) proteins and a cancer target antigen, comprising: assaying for baseline cell surface expression levels of the one or more ALPP proteins in a biological sample obtained from the patient; and assaying for co-expression of one or more cancer cell surface oncogenic drivers.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A hybrid cellular and non-cellular multi-hop communication device, including a hand-held wireless device having one or more antennas, a cellular wireless interface connected to at least some of the one or more antennas, and a non-cellular wireless interface connected to at least some of the one or more antennas. The non-cellular wireless interface may include a rate allocator configured to select a physical-layer rate of transmission of data from the non-cellular wireless interface based on a queue length of data to be transmitted from the hand-held cellular device and a transmitter configured to wirelessly transmit data from the queue and adjust physical-layer transmission parameters based on a physical-layer rate selected by the rate allocator.

IPC Classes  ?

• H04W 72/542 - Allocation or scheduling criteria for wireless resources based on quality criteria using measured or perceived quality
• H04K 3/00 - Jamming of communicationCounter-measures
• H04W 16/14 - Spectrum sharing arrangements
• H04W 28/22 - Negotiating communication rate
• H04W 72/02 - Selection of wireless resources by user or terminal
• H04W 72/52 - Allocation or scheduling criteria for wireless resources based on load
• H04W 72/541 - Allocation or scheduling criteria for wireless resources based on quality criteria using the level of interference
• H04W 88/06 - Terminal devices adapted for operation in multiple networks, e.g. multi-mode terminals

Abstract

A non-volatile magnetoresistive random-access memory device is provided. The device comprises a three-terminal spin-orbit torque magnetic tunnel junction (MTJ) with perpendicular anisotropy. The MTJ comprises a fixed ferromagnetic layer, a free ferromagnetic layer, a tunnel barrier between the fixed and free ferromagnetic layers, and a heavy metal layer under the free ferromagnetic layer. A read access transistor is connected to a first terminal of the fixed magnetic layer. A write access transistor is connected to a second terminal of the heavy metal layer. A ground voltage is connected to a third terminal of the heavy metal layer. A read bit line is connected to the read access transistor, and a read word line is connected to the gate of the read access transistor. A write bit line is connected to the write access transistor, and a write word line is connected to the gate of the write access transistor.

IPC Classes  ?

• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
• H01F 10/32 - Spin-exchange-coupled multilayers, e.g. nanostructured superlattices
• H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices
• H10N 50/10 - Magnetoresistive devices
• H10N 50/80 - Constructional details

Abstract

A method of performing a diagnostic scan of a subject comprises defining a set of data acquisition parameter sequences, defining a set of upper bounds and a set of lower bounds for each of the set of data acquisition parameter sequences, defining a set of representative tissue parameters for a tissue of the subject, selecting a set of basis functions, calculating values for a set of basis function coefficients to yield a piecewise polynomial representation of each of the set of data acquisition parameter sequences within the sets of upper and lower bounds based on the set of desired tissue parameters, and performing a diagnostic scan of the subject using the calculated data acquisition parameter sequences.

IPC Classes  ?

• G01R 33/54 - Signal processing systems, e.g. using pulse sequences
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/48 - NMR imaging systems

Abstract

The present disclosure provides compositions with probiotic microbes, including one or more of Bacteroides finegoldii, Bacteroides caccae, Bacteroides ovatus, Bacteroides uniformis, Parabacteroides distasonis, Alistipes onderdonkii, Anaerobutyricum hallii, or Gemmiger formicilis, that provide hepatoprotective activity in a subject. Further disclosed herein are methods for determining whether a subject has or is at risk of developing liver disease and associated methods for monitoring liver disease progression during treatment.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

Gram-negative bacterial cells for expression and secretion of heterologous peptides are disclosed. The bacterial cells include a first nucleic acid encoding a secretion signal sequence, e.g., a microcin secretion signal sequence, fused to a heterologous peptide, a second nucleic acid encoding a C39 peptidase-containing ATP-binding cassette transporter (PCAT), and a third nucleic acid encoding a membrane fusion protein. The gram-negative bacterial cells secrete the heterologous peptide from the bacterial cytosol to an external environment outside of the bacterial outer membrane. Methods for preparation and delivery of peptides to external environments are also described.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• C07K 14/245 - Escherichia (G)

Abstract

The present invention relates to the treatment of disorders associated with oxidative stress and provides small synthetically derived compounds for treating such disorders. The disclosure is directed to a specific new class of thio based compounds which target a particular regulator of the antioxidant response and are shown to be useful in the treatment of disorders associated with oxidative stress, such as the alleviation of pain, for instance, neuropathic pain.

IPC Classes  ?

• C07C 323/52 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The present disclosure is directed to compositions and methods comprising biomarker genes for identifying or classifying a subject's response to a RAS inhibitor therapies and combination therapies. Methods of treating a tumor in a subject comprising administering to the subject an amount of a RAS inhibitor and an amount of a JAK/STAT pathway inhibitor, a WNT/b-catenin pathway inhibitor, an NFkB inhibitor, a TGFb pathway inhibitor, an FGF pathway inhibitor or a mucin inhibitor, effective to treat a tumor. Methods of treating a tumor resistant to a RAS inhibitor therapy comprising administering to a tumor so identified an amount of a RAS inhibitor and an amount of a JAK/STAT pathway inhibitor, a WNT/b-catenin pathway inhibitor, an NFkB inhibitor, a TGFb pathway inhibitor, an FGF pathway inhibitor or a mucin inhibitor, effective to treat a tumor resistant to a RAS inhibitor therapy.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

An exemplary system and method that employ inverse-problem analysis that can determine spatially-varying mechanical parameters in a spatially-varying field of a heterogeneous material. Mathematically, the computation simultaneously poses the inversion program and an image registration problem in a continuum limit function space setting to derive a discretization dimension-independent algorithm for the robust inference of heterogeneous material properties. The algorithm can operate using two or more images of a speckled pattern or other non-uniform patterns applied to, or observable of, the surface of the material in a first state and a second state different from the first state. The difference can be used to assess, via a Newtonian-based operator, the infinite-dimensional spatial fields as state variables that are regularized via a regularization model to constrain the inherent ill-posed nature of inverse problems.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

An integral molten salt nuclear reactor includes a drain tank section configured to hold a volume of fuel salt. The integral molten salt nuclear reactor further includes a reactor section configured to receive the volume of fuel salt from the drain tank and cause fission reactions that heats the molten salt. The integral molten salt nuclear reactor further includes a heat exchange section configured to receive a flow of the heated fuel salt from the reactor section and remove heat therefrom.

IPC Classes  ?

• G21C 1/32 - Integral reactors, i.e. reactors wherein parts functionally associated with the reactor but not essential to the reaction, e.g. heat exchangers, are disposed inside the enclosure with the core
• G21C 3/54 - Fused salt, oxide, or hydroxide compositions
• G21C 7/30 - Control of nuclear reaction by displacement of reactor fuel or fuel elements

Abstract

Embodiments of the present disclosure pertains to a genetically altered bacterial strain that lacks functional versions of at least three of the following proteins: FbpA; SapM; Zmp1; DosR; FadD26; SigH; nuoG; and Eis. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: FbpA; SapM; Zmp1; and DosR. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: FbpA; SapM; Zmp1; DosR; FadD26; and SigH. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: SapM; Zmp1; and nuoG. Further embodiments of the present disclosure pertain to methods of treating or preventing a bacterial infection in a subject by administering to the subject a bacterial strain of the present disclosure. In some embodiments, the bacterial infection is tuberculosis.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/06 - Antibacterial agents for tuberculosis
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/32 - Mycobacterium

Abstract

Apparatuses and methods to generate high frequency shock waves in a controlled manner. The generated shock waves can be delivered to certain cellular structures of a patient for use in medical and/or aesthetic therapeutic applications. The shock waves can be configured to impose sufficient mechanical stress to the targeted cells of the tissue to rupture the targeted cells. Embodiments of the apparatuses and methods of the present invention provide targeted rupturing of specific cells without damaging side effects such as cavitation or thermal degradation of surrounding non-targeted cells.

IPC Classes  ?

• A61N 7/00 - Ultrasound therapy
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Methods and compositions related to thermogenic adipose for study and therapeutics are described. Certain embodiments are directed to vascularized thermogenic adipose tissue developed using microvascular fragments (MVFs). MVFs are isolated and thermogenic adipose formed.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
• A61P 31/04 - Antibacterial agents
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

axyzcc, wherein the cathode material comprises at least two phases, wherein a first phase is an olivine phase, and a second phase, and wherein the olivine phase is present in an amount greater than 90 wt% based on the total weight of the at least two phases, wherein 1 ≤ a ≤ 1.2 wherein 0.4 ≤ x ≤ 0.8, wherein 0.2 ≤ y ≤ 0.6, wherein 1 ≤ c ≤ 1.1, wherein D comprises one or more cations different from Li+, Mn2+,and Fe2+, wherein D comprises at least Al3+and Si4+, and wherein at least an amount of Al3+and Si4+is present in the second phase; wherein z is a total amount of moles of D present and is 0.01 ≤ z ≤ 0.1 wherein x + y + z = 1; and wherein the cathode material exhibits an electrode press density of greater than 2.2 g cm-3; and an electrode volumetric density equal to or greater than 1200 Wh L-1.

IPC Classes  ?

• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• H01M 10/052 - Li-accumulators

Abstract

Provided are compositions and methods for treating hypoxia-related conditions. The compositions comprise a hypoxia-inducible factor (HIF) interfering nucleic acid encapsulated by a neutral or positively charged phospholipid component. Also provided are methods of making the disclosed compositions.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Embodiments are directed to a computer-implemented method for regulating graphics frame rendering and encoding rates. The method including synchronizing a frame rate of rendering graphics frames by a 3D application executing in a cloud server with a frame rate of encoding rendered graphics frames at a proxy server; and synchronizing the frame rate of encoding the rendered graphics frames at the proxy server with a frame rate of transmitting the encoded graphics frames to a client device over a network.

IPC Classes  ?

• H04N 7/01 - Conversion of standards
• G06T 1/20 - Processor architecturesProcessor configuration, e.g. pipelining
• G06T 9/00 - Image coding

Abstract

We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

Apparatuses and methods for electrohydraulic generation of shockwaves at a rate of between 10 Hz and 5 MHz, and/or that permit a user to view a region of a patient comprising target cells during application of generated shockwaves to the region. Methods of applying electro-hydraulically generated shockwaves to target tissues (e.g., for reducing the appearance of tattoos, treatment or reduction of certain conditions and/or maladies).

IPC Classes  ?

• A61N 7/00 - Ultrasound therapy
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 17/225 - Surgical instruments, devices or methods for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• G10K 11/26 - Sound-focusing or directing, e.g. scanning
• G10K 15/04 - Sound-producing devices

Abstract

A stacked-design, conformable and mobile sensor that, when worn on an epidermis of a person can be used to continuously detect and monitor whole-body hydration in real time comprising a first flexible, stretchable insulating substrate comprising two or more current injection electrodes and one or more voltage electrodes comprised of biocompatible materials and formed on a first side of the flexible, stretchable insulating substrate and each electrode is configured to flex and stretch with the flexible, stretchable insulating substrate.

IPC Classes  ?

• A61B 5/0537 - Measuring body composition by impedance, e.g. tissue hydration or fat content
• A61B 5/25 - Bioelectric electrodes therefor
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Methods and devices are directed to PT and aPTT testing tailored for home care or point-of-care applications. The approach is based on a unique detection mechanism that measures the changes in the refractive index of a blood sample during its coagulation process in a capillary. The methods and/or associated devices provide patients with the ability to monitor their clotting status conveniently at home.

IPC Classes  ?

• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time
• G01N 21/41 - RefractivityPhase-affecting properties, e.g. optical path length

Abstract

Disclosed herein are composite materials and methods of making and use thereof. The composite materials can comprise: a porous periodic nanolattice layer having a first refractive index, and a continuous layer having a second refractive index and being disposed on the porous periodic nanolattice layer; the first refractive index and the second refractive index being different; wherein the porous periodic nanolattice layer comprises a plurality of pores defined by a nanolattice formed of hollow members, the plurality of pores being periodic. Also disclosed herein are methods of making a composite material, the methods comprising: forming a patterned layer; depositing a first material on the patterned layer, thereby forming a coated patterned layer; depositing a buffer material layer on the coated patterned layer, thereby forming a planarized layer; depositing a continuous layer on the planarized layer; and removing the buffer material layer and the patterned layer, thereby forming the composite material.

IPC Classes  ?

• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

In vitro and in vivo methods for screening for targets for cancer therapy are provided herein. Methods contemplate screening for targets that contribute to the immunosuppressive environment for the tumor cells, especially those targets that are associated with radiation treatment. Thus, methods provided herein are useful for identifying potential targets useful for providing cancer therapeutic agents that can be used either alone or in combination with radiation therapy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/42 - Cancer antigens
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a carbohydrate-polymer conjugate comprising a repeat unit, a divalent linker, and a carbohydrate and compositions thereof, wherein the repeat unit comprises, in part, a linker and a carbohydrate, and a method comprising the step of administering a composition comprising the carbohydrate-polymer conjugate, wherein the composition can cross the blood-brain barrier.

IPC Classes  ?

• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 9/51 - Nanocapsules
• A61P 35/00 - Antineoplastic agents
• A61P 45/06 -

Abstract

Provided herein are methods for the production of tissue resident memory-like T cells by the combination of hypoxia and TGFβ. Further provided herein are methods of using the tissue resident memory T cells as adoptive cell therapy.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/42 - Cancer antigens
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

In directional drilling, a nonlinear Delay Differential Equation (DDE) model may be used for its high precision in predicting how a borehole may be drilled according to a well plan. To address challenges associated with real-time control of a drill drilling wellbore, techniques of generalized feedback linearization, finite element concept, and zero-order hold discretization may be used to transform a nonlinear DDE model into discretized domain with a linear Ordinary Differential Equation (ODE) form. Following this transformation, a novel optimization framework may be used to concurrently determine optimal control inputs and solve a linear complementarity problem (LCP). The validity of both the discretized model and the optimization strategy may be verified by comparing modeled results with real-world results. Subsequent closed-loop simulations demonstrate the ability of the proposed model predictive control to maintain alignment of a drill string with a planned well trajectory, even in the presence of disturbances and noise.

IPC Classes  ?

• G01V 3/30 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation specially adapted for well-logging operating with electromagnetic waves
• G01V 1/40 - SeismologySeismic or acoustic prospecting or detecting specially adapted for well-logging
• E21B 47/12 - Means for transmitting measuring-signals or control signals from the well to the surface, or from the surface to the well, e.g. for logging while drilling
• E21B 47/02 - Determining slope or direction

Abstract

The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

In an embodiment, the present disclosure pertains to a composition. In some embodiments, the composition includes a cross-linked network of cyclic macromolecules. In some embodiments, the cyclic macromolecules are covalently cross-linked to one another by a plurality of cross-linking agents. In some embodiments, at least some of the cross-linking agents are covalently functionalized with a plurality of functional groups. In some embodiments, the plurality of functional groups include a chain of at least three atoms that protrude out of the cross-linking agents. In some embodiments, the cross-linking agents and the functional groups form a polymer matrix, such as poly (β-amino ester). In some embodiments, the composition is in the form of particles. In another embodiment, the present disclosure pertains to a method of administering an active agent to a subject. In some embodiments, the method includes administering a composition of the present disclosure to the subject.

IPC Classes  ?

• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 9/51 - Nanocapsules
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems

Abstract

A micro- or nanotextured or structured surface and methods of making and using the same are provided. A structured or textured surface can comprise a substrate and a textured surface comprising a plurality of features and configured to reduce surface adhesion of a particulate to the structured surface. The micro- or nanotextured surface can be replicated using highly scalable processes, such as roll-to-roll nanoimprint lithography and roll-to-roll thermal embossing onto the substrate by a master mold, which can be created by ultrasonic nanocoining.

IPC Classes  ?

• B08B 17/06 - Preventing deposition of fouling or of dust by giving articles subject to fouling a special shape for arrangement
• B29C 33/38 - Moulds or coresDetails thereof or accessories therefor characterised by the material or the manufacturing process
• B29C 33/42 - Moulds or coresDetails thereof or accessories therefor characterised by the shape of the moulding surface, e.g. ribs or grooves
• B29C 59/02 - Surface shaping, e.g. embossingApparatus therefor by mechanical means, e.g. pressing
• B29K 69/00 - Use of polycarbonates as moulding material
• B29K 79/00 - Use of other polymers having nitrogen, with or without oxygen or carbon only, in the main chain, as moulding material

Abstract

Scanning probe systems and control methods are disclosed in which probe-sample separation is dynamically regulated based on a derivative of a tunneling signal. In some cases, a modulation signal is applied to a control signal associated with an actuator configured to adjust a probe relative to a surface. A tunneling current induced between the probe and the surface is converted into a tunneling signal, from which a derivative signal is obtained based at least in part on the modulation. A feedback processor determines a control metric based on the derivative signal and adjusts the control signal to maintain the control metric substantially constant during scanning. In some implementations, the derivative signal is proportional to a natural logarithm of a transimpedance-scaled rate of change of tunneling current with respect to probe-surface separation. Multi-tip configurations and lock-in amplifier-based demodulation are also described. Some disclosed techniques facilitate enhanced probe control and topography imaging performance in scanning tunneling microscopy and related systems.

IPC Classes  ?

• G01Q 10/06 - Circuits or algorithms therefor
• G01Q 60/16 - Probes, their manufacture or their related instrumentation, e.g. holders

Abstract

Provided herein are methods for producing an isolated population of prepared NK cells. In particular embodiments, prepared NK cells are expanded for a certain duration of time. In particular embodiments, prepared NK cells are expanded in one or more certain media(s). Further provided herein are compositions for preparing NK cells, compositions comprising prepared NK cells, and methods for the treatment of disease by administering the prepared NK cells.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells

Abstract

Disclosed herein are compounds, and salts thereof, which inhibit targeted NRAS mutants, pharmaceutical formulations, and methods of treatment of NRAS-mediated diseases, such as certain cancers.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/33 - Heterocyclic compounds

Abstract

In directional drilling, a nonlinear Delay Differential Equation (DDE) model may be used for its high precision in predicting how a borehole may be drilled according to a well plan. To address challenges associated with real-time control of a drill drilling wellbore, techniques of generalized feedback linearization, finite element concept, and zero-order hold discretization may be used to transform a nonlinear DDE model into discretized domain with a linear Ordinary Differential Equation (ODE) form. Following this transformation, a novel optimization framework may be used to concurrently determine optimal control inputs and solve a linear complementarity problem (LCP). The validity of both the discretized model and the optimization strategy may be verified by comparing modeled results with real-world results. Subsequent closed-loop simulations demonstrate the ability of the proposed model predictive control to maintain alignment of a drill string with a planned well trajectory, even in the presence of disturbances and noise.

IPC Classes  ?

• E21B 44/00 - Automatic control systems specially adapted for drilling operations, i.e. self-operating systems which function to carry out or modify a drilling operation without intervention of a human operator, e.g. computer-controlled drilling systemsSystems specially adapted for monitoring a plurality of drilling variables or conditions
• E21B 7/10 - Correction of deflected boreholes
• E21B 17/10 - Wear protectorsCentralising devices

Abstract

Various DNAzyme-based fluorescence sensors can be used to detect metal ions of various oxidation states. They are made of two different DNA strands, one called the substrate strand, and the other called the enzyme strand (E) which can catalyze the cleavage of the RNA base in the presence of specific target molecule. DNAzymes can be applied for high special and temporal resolution imaging of target ions in living cells and tissues with high specificity.

IPC Classes  ?

• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 21/64 - FluorescencePhosphorescence

Abstract

In one aspect, methods of treating and/or imaging biological tissue or a biological compartment are described herein. In some embodiments, a method comprises disposing a population of agents, such as a therapeutic agent, imaging agent, theranostic agent, or other agent in the biological compartment. The method further comprises applying a focused ultrasound beam to a first target region of the biological compartment to compress at least a portion of the first target region, and subsequently removing the focused ultrasound beam from the first target region to end the compression or compressive force applied to the first target region. In some cases, the focused ultrasound beam has a duty cycle greater than 5% and/or a frequency of 1-30 MHz. In some instances, applying the ultrasound beam creates a first order ultrasound oscillation wave within the biological compartment having a pressure gradient in one or more dimensions of 0.1 to 10 MPa/mm.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61K 49/22 - Echographic preparationsUltrasound imaging preparations

Abstract

Embodiments of the disclosure encompass improvements on cell therapies by allowing the cells to be more effective for cancer treatment, including in a solid tumor microenvironment. In specific cases, the cells are modified to have reduced or inhibited levels of expression of GPR4, GPR31, GPR68, GPR81, GPR132, GPR151, CREM, ICER, or CREB1, such as by CRISPR gene editing. In certain cases, the cells are modified to have reduced or inhibited levels of expression of CREM. In certain cases, the cells are further modified to express, for example, one or more engineered receptors, one or more cytokines, and/or optionally one or more suicide genes.

IPC Classes  ?

• A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present disclosure provides methods and compositions for prognosing and treating acute myeloid leukemia. The present disclosure further provides methods and compositions of identifying a prognostic risk comprising detecting the expression level of at least two proteins selected from the group consisting of FGF23, GFAP, IFNL1, IL33, MUC16, OSMR, LCN2, PDGFA, and VSNL1.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

Embodiments of the disclosure include methods and compositions for treating minimal residual disease in an individual. In specific embodiments, the disclosure concerns methods of treating an individual with minimal residual disease with one or more inhibitors of CSF-1R and/or one or more inhibitors of CSF-1. In specific embodiments, the individual is positive for the presence of mutated circulating tumor DNA (ctDNA), and/or the individual has colorectal cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/04 - Antineoplastic agents specific for metastasis
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present disclosure presents systems and methods for creating and recording digital cyber-physical passports during a manufacturing process. One such system or method is adapted to supply manufacturing data and software data for a particular physical part instance being manufactured by the manufacturing machine; track a progress of the manufactured part instance and store the manufacturing and software data supplied by the one or more monitoring devices and/or the manufacturing machine in a data store; generate digital cyber-physical passports for each completed phase of manufacturing for the particular part instance, wherein the cyber-physical passport contains the software data associated with the physical part instance, wherein the software data indicates a software application that is used during a manufacturing phase for the particular physical part instance; and record individual cyber-physical passports on a cyber-physical passport-linked ledger on a distributed ledger technology platform during the manufacturing process of the part instance.

IPC Classes  ?

• G05B 19/04 - Programme control other than numerical control, i.e. in sequence controllers or logic controllers

Abstract

A system and method for visualizing blood flow are disclosed. The method generally includes obtaining a laser speckle contrast imaging (LSCI) image of blood flow; obtaining a white light image of a tissue, the white light image capturing an anatomical structure of a subject in a region associated with the LSCI image of the blood flow; spatially registering the LSCI image and the white light image with one another; overlaying the spatially registered LSCI and white light images; and generating display data which includes the spatially registered LSCI and white light images and that continuously depicts the blood flow overlaying the tissue.

IPC Classes  ?

• A61B 5/026 - Measuring blood flow
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0275 - Measuring blood flow using tracers, e.g. dye dilution
• G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
• G06T 11/00 - 2D [Two Dimensional] image generation
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

An orthopedic guidewire positioning device comprising: an elongated sheath extending between a proximal end and a distal end; the elongated sheath further comprising a guidewire channel extending through the elongated sheath to a guidewire opening at the distal end of the elongated sheath, the guidewire channel configured to receive a guidewire such that a distal end of the guidewire extends out of the guidewire opening at the distal end of the elongated sheath; an inflatable member proximate the distal end of the elongated sheath, the device configured to inflate the inflatable member such that the inflatable member extends away from a first side of the elongated sheath as it inflates to deflect the distal end of the elongated sheath in a direction opposite a direction along which the inflatable member extends.

IPC Classes  ?

• A61B 17/88 - Methods or means for implanting or extracting internal fixation devices
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61M 25/09 - Guide wires

Abstract

A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61K 36/734 - Crataegus (hawthorn)
• A61K 38/44 - Oxidoreductases (1)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Embodiments of the invention provide a solution to the problems associated with the lack of treatments for MARV and RAVV. The inventors have generated neutralizing mAbs to MARV that neutralize MARY infection. Certain mAbs are cross-reactive to MARV and RAVV.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/46 - Hybrid immunoglobulins
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present disclosure relates to pharmaceutical compositions for editing genes that can be administered through inhalation, such as via nebulization. In particular, these compositions contain β-sitosterol instead of other sterols or steroids. These compositions may show improved gene editing performance with fewer editing errors and/or improved aerosolization compared to lipid nanoparticles with cholesterol.

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/14 - Particulate form, e.g. powders
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Abstract

Methods described herein provide procedures that can be used to rapidly screen drugs for high probability of effectiveness as therapy for amyloid associated neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, and prion-associated diseases by detecting size and/or aggregation of phage incubated with a target compound. The data generated indicate that bacteriophage or phage capsid subunits can switch conformation to a conformation that mimics the neurodegenerative disease-causing conformation of amyloid proteins. This switch has been observed by incubation of bacteriophage T4 with methylene blue, a compound for which literature data indicates has anti-AD activity.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• G01N 33/483 - Physical analysis of biological material
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials

Abstract

Provided herein are engineered proteins comprising engineered CCHFV glycoprotein ectodomain. Such engineered CCHFV glycoprotein ectodomains may exhibit improved conformational homogeneity and/or biophysical stability. The ectodomains may be incorporated into nanoparticles or virus-like particles. Methods are also provided for use of the engineered CCHFV glycoprotein ectodomains as diagnostics, in screening platforms, and/or in vaccine compositions.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors
• A61K 39/12 - Viral antigens
• C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Embodiments of the disclosure include methods and compositions for treating minimal residual disease in an individual. In specific embodiments, the disclosure concerns methods of treating an individual with minimal residual disease with one or more inhibitors of CSF-1R and/or one or more inhibitors of CSF-1. In specific embodiments, the individual is positive for the presence of mutated circulating tumor DNA (ctDNA), and/or the individual has colorectal cancer.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Genetically modified HIV-1 variants capable of infecting owl monkeys that includes one or more novel point mutations coupled with the replacement of the viral infectivity factor (Vif) gene.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Methods are provided for the isolation and analysis of circular DNA from complex samples, based on the topology of the DNA molecule. A sample comprising DNA species is combined with a chaotropic dense salt solution. A fraction containing the circular DNA of interest is isolated and dialyzed to remove excess salt. In some embodiments salt gradients are generated by ultracentrifugation in the absence of intercalating dyes, e.g. ethidium bromide; and in the absence of protease digestion. The circular DNA thus isolated is substantially pure, e.g. greater than about 75%, greater than about 80%, greater than about 90%, greater than about 95% of DNA in the isolated fraction is comprised of circular DNA.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Disclosed are approaches to data acquisition, analysis, and computational forecasting that employs quantitative MRI data to predict the response of cancer to therapy. Example protocols detail how to acquire needed images followed by registration, segmentation, quantitative perfusion and diffusion analysis, model calibration, and prediction. The response of individual cancer patients to therapy is forecast by application of a biophysical, reaction-diffusion model to these data. Application of the protocol results in coregistered MRI data from at least two scan visits that quantifies an individual tumor's size, cellularity and vascular properties. This enables a spatially resolved prediction of how a particular patient's tumor will respond to therapy. A modified therapy can be determined based on predicted response.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/00 - Image analysis
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

IPC Classes  ?

• C07D 495/04 - Ortho-condensed systems
• C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Abstract

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

A device including an interface body. The interface body includes a flexible electrode array. The flexible electrode array includes one or more encapsulation layers, one or more electrodes disposed towards a distal end of the flexible electrode array and one or more electrode contact pads, each one of the electrode contact pads contacting one of the electrodes. The interface body also includes a softening polymer layer in direct contact with a surface of at least a portion of at least one of the encapsulation layers. A Young's modulus of the softening polymer layer is decreased by at least 50 percent when wet and at an elevated temperature of at least 35 °C as compared to the Young's modulus of the softening polymer layer when dry and at room temperature.

IPC Classes  ?

• A61L 31/14 - Materials characterised by their function or physical properties
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• H05K 1/03 - Use of materials for the substrate
• H05K 3/40 - Forming printed elements for providing electric connections to or between printed circuits
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof

Abstract

Separation of isotopes (or atomic species) can use laser pumping in combination with an optical resonator. Neutral atoms propagating as a beam are exposed to one or more pumping lasers that selectively excite a target isotope (or target atomic species) into an excited state. An optical resonator is locked in transmission to a separate laser that is tuned to a wavelength that selectively ionizes the excited isotope (or atomic species). The resulting ions can be collected, e.g., using an electrically-charged plate or other collector.

IPC Classes  ?

• B01D 59/50 - Separation involving two or more processes covered by different groups selected from groups , , , , , , , ,
• H01J 49/10 - Ion sourcesIon guns
• H01S 3/091 - Processes or apparatus for excitation, e.g. pumping using optical pumping
• B01D 59/34 - Separation by photochemical methods

Abstract

In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The present disclosure compounds of the formulae: The present disclosure compounds of the formulae: The present disclosure compounds of the formulae: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods for the use of said compounds and/or pharmaceutical compositions, such as in the treatment of cancer.

IPC Classes  ?

• C07C 235/56 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• A61P 35/00 - Antineoplastic agents
• C07D 215/38 - Nitrogen atoms
• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 233/88 - Nitrogen atoms, e.g. allantoin

Abstract

Aspects are directed to a novel small molecule inhibitor of Nsp16 having a chemical formula of (N-[9-[(2R,3R,4S,5S)-5-(chloromethyl)-3,4-dihydroxy-tetrahydrofuran-2-yl]purin-6-yl]prop-2-enamide) (AT501) or analogs thereof. Other aspects are directed to a therapeutic composition comprising AT501 or analogs thereof, further including antiviral compounds or anticancer compounds. Certain aspects are directed to a method of treating Coronavirus infection by administering AT501 or a composition thereof to a subject having or at risk of obtaining a Coronavirus infection caused by SARS-CoV-1 or SARS-CoV-2 virus. Certain aspects are directed to methods of treating cancer by administering AT501 or a composition thereof to a subject having or at risk of developing cancer, such as leukemia.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 31/52 - Purines, e.g. adenine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical

Abstract

The disclosed subject matter relates to compostions comprising ursolic acid or pharmaceutically acceptable salts thereof and curcumin or pharmaceutically acceptable salts thereof. Further, disclosed herein are methods of using ursolic acid or pharmaceutically acceptable salts thereof and curcumin or pharmaceutically acceptable salts thereof for treating, inhibiting initiation, inhibiting progression, and/or inhibiting metastasis of cancer, such as prostate cancer, in a subject.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/12 - Ketones

Abstract

The present invention relates to a polymer comprising a repeat unit, a divalent linker, and a negatively charged functional group, as well as a method of synthesizing a polymer using ring¬ opening metathesis polymerization (ROMP) and a method of removing at least one solute from a solution.

IPC Classes  ?

• C04B 26/02 - Macromolecular compounds
• C04B 26/04 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
• C08F 12/02 - Monomers containing only one unsaturated aliphatic radical
• B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography

Abstract

Provided are compositions and methods for modulating methylation and/or expression of one or more target nucleic acids in a cell. Also provided are methods of making the disclosed compositions and methods of treating a disease or condition associated with increased methylation of a target nucleic acid by administering a disclosed composition.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• A61K 38/45 - Transferases (2)
• A61K 38/46 - Hydrolases (3)
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors
• C12N 9/10 - Transferases (2.)